Bioeconomy: Germany to lose pole positionThe German Bioeconomy Council said policymakers would risk Germany’s leadership in bioeconomy if they dont capitalise on new technology options resulting from the ongoing merger of digital and bio … more ➔
Eylea met Phase III endpoint in diabetic r... VEGF blocker Eylea (aflibercept), which is co-developed for eye diseases by Bayer HealthCare and Regeneron under a deal signed in 2006, has met the 24-week primary endpoint of the pivotal Panorama Phase … more ➔
Lundbeck acquiring Prexton in €905m dealH. Lundbeck A/S has announced it will acquire Dutch Prexton Therapeutics B.V., a one-programme company developing the allosteric metabotropic glutamate receptor subtype 4 (mGluR4) modulator foliglurax … more ➔
Stroke alarmin spurs further emboliesResearchers from Sweden, Switzerland, France, Italy, and Germany report that expression of a post-stroke factor boost arterial plaque formation. The identification of the new target might open up an … more ➔
Algorithm tracks cancer type down to methy...Researchers have applied a self-learning algorithm to distinguish the almost 100 brain cancer types through their methylation pattern in a routine diagnostic setting. The method eliminates inter-pathologist … more ➔
Business as usual in AmsterdamThe tremendous success of last years BIO Europe Spring in Barcelona was hard to beat. But the follow-up this year in Amsterdam organised by EBD Group together with Health Holland crystallised … more ➔
MYR Pharma completes chronic hepatitis del...German MYR Pharma has completed a proof of concept Phase IIb trial with its first-in-class hepatitis D entry inhibitor Myrcludex B, which is developed under the European Medicines Agencys PRIME … more ➔
Sanofis alirocumab improves cardiovascul...Alirocumab, Sanofi s/Regenerons PCSK9 inhibitor, in combination with statins has met the endpoint of reducing the number of major adverse cardiovascular events (MACE) over statin monotherapy … more ➔
Medimmune finds target against systemic sc...Researchers at Medimmune, AstraZeneca’s biologics arm, have identified a mechanism that drives the autoimmune disease systemic sclerosis. more ➔
Bioprocessing challenges in the focusAbout 300 bioeconomy experts from science and business came together in Strasbourg for the first edition of BIOKET to discuss up-scaling challenges, new processing technologies as well as the potential … more ➔
